Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paris Charilaou

Gastroenterology Charlotte, NC Medical Doctor

NPI 1457734659 CMS profile 5700175

1025 Morehead Medical Dr, Ste 300, Charlotte, NC 28204

Open in the dashboard

General payments

$11,888

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$55,766 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Paris Charilaou of Charlotte, NC is reported in the CMS Open Payments database as having received $11,888 across 188 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $55,766 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,891 60
2024 General $984 45
2023 General $2,232 48
2022 General $4,182 18
2021 General $305 6
2020 General $57 4
2019 General $237 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paris Charilaou
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Paris Charilaou were reported at $3,891. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Paris Charilaou Gastroenterology median Middle half National median
2019 $237 $417 $126–$1,100 $163
2020 $57 $224 $74–$624 $114
2021 $305 $352 $106–$1,054 $132
2022 $4,182 $448 $129–$1,270 $149
2023 $2,232 $533 $150–$1,390 $160
2024 $984 $605 $160–$1,606 $164
2025 $3,891 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $5,267 100 payments
  2. Pfizer Inc. $3,235 15 payments
  3. Janssen Research & Development, LLC $1,151 12 payments
  4. Janssen Biotech, Inc. $968 28 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $402 11 payments
  6. Janssen Scientific Affairs, LLC $324 4 payments
  7. Lilly USA, LLC $218 6 payments
  8. Celgene Corporation $196 5 payments
  9. Boston Scientific Corporation $57 3 payments
  10. Sandoz Inc. $35 2 payments
  11. Other $36 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,800 2 payments
  2. Food and Beverage $4,850 176 payments
  3. Travel and Lodging $953 6 payments
  4. Education $285 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $3,655 59 payments
  2. XELJANZ $3,153 11 payments
  3. SKYRIZI Immunology $965 40 payments
  4. STELARA $904 23 payments
  5. SKYRIZI Immunology $468 32 payments
  6. TREMFYA $402 10 payments
  7. HUMIRA $312 14 payments
  8. ENTYVIO $290 10 payments
  9. VELSIPITY $214 11 payments
  10. ZEPOSIA $196 5 payments
  11. Other $439 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

356

Median for Gastroenterology: 569

Drug cost

$793,628

Median for Gastroenterology: $104,976

Branded share of claims

61.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi On-Body Risankizumab-Rzaa Brand 32 $628,341
Rinvoq Upadacitinib Brand 14 $142,266
Motegrity Prucalopride Succinate Brand 13 $7,007
Mesalamine Generic 25 $4,696
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 53 $3,402
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 20 $2,488
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 14 $1,996
Ciprofloxacin Hcl Generic 25 $1,204
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 43 $742
Omeprazole Generic 44 $647

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$23,696

Medicare's payments for the services billed

Medicare patients

103

Average age 71

Services billed

303

61 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 35%
Chronic kidney disease 33%
Depression 30%
Diabetes 20%
Osteoporosis 20%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $251
  • Janssen Scientific Affairs, LLC $143
$394 — —
SKYRIZI
  • AbbVie, Inc. $193
$193 32 —
TREMFYA
  • Janssen Scientific Affairs, LLC $149
  • Janssen Biotech, Inc. $18
$167 — —
RINVOQ
  • AbbVie, Inc. $80
$80 14 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record